BCAA Therapy for TBI Cognitive and Sleep Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective in mitigating or preventing the cognitive and sleep-related impairments caused by traumatic brain injury (TBI), which result from imbalances in excitatory and inhibitory synaptic activity and altered neuronal and astrocytic metabolism.
Innovation Solution
Administration of branched chain amino acids (BCAAs), particularly valine, leucine, and isoleucine, either orally or through compositions with pharmaceutically acceptable carriers, to restore metabolic balance and improve cognitive function and sleep disturbances in TBI subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat TBI, then treatment is provided, but cognitive and sleep-related impairments are not effectively mitigated or prevented
Solution Approach 1:
The patent applies parameter changes by modifying the metabolic parameters of the brain through BCAA supplementation. Specifically, it changes the amino acid composition in the brain by administering BCAAs orally, which alters neuronal and astrocytic metabolism, restores excitatory-inhibitory balance, and improves cognitive and sleep functions. This biochemical parameter change directly addresses the metabolic alterations caused by TBI.
2Reliability
If BCAAs are administered to restore metabolic balance, then cognitive function and sleep patterns improve, but the mechanism of action is not fully understood
Solution Approach 1:
The patent identifies astrocyte-derived metabolites as intermediary substances that mediate the interaction between astrocytic and neuronal metabolism. BCAAs influence these intermediary metabolites, which then affect neuronal function. This intermediary mechanism explains how astrocyte metabolic changes translate to neuronal functional improvements without requiring direct neuron-to-neuron communication.
3Strength
If TBI occurs, then brain injury is sustained, but regional imbalances in excitatory and inhibitory synaptic activity occur
Solution Approach 1:
The patent changes the biochemical parameters of synaptic transmission by introducing BCAAs, which alter the excitatory-inhibitory balance. The BCAAs modify neurotransmitter synthesis, release, and reuptake mechanisms, thereby restoring the stability of synaptic activity composition affected by TBI.
Data Source
AI summary
Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury.